Download PDF
Pharmacopsychiatry 2003; 36(2): 83-86
DOI: 10.1055/s-2003-39046
Letter
© Georg Thieme Verlag Stuttgart · New York

Successful Antimanic Treatment and Mood Stabilization with Lamotrigine, Clozapine, and Valproate in a Bipolar Patient after Lithium-induced Cerebellar Deterioration

A Case ReportC. Dembowski1 , T. Rechlin1
  • 1Department of Psychiatry and Psychotherapy, District Hospital Rendsburg, Germany
Further Information

Publication History

Received: 8.2.2002 Revised: 19.3.2002

Accepted: 19.6.2002

Publication Date:
06 May 2003 (online)

Also available at
    Permissions and Reprints

We report the case of a 56-year-old male with an 18-year history of a bipolar I affective disorder (DSM-IV criteria), who has been successfully treated with lithium for 8 years. When lithium was discontinued due to a lithium-induced persistent cerebellar syndrome at therapeutic lithium levels, the combination of valproate and clozapine was less effective to achieve mood stabilization. A re-challenge with lithium failed due to impairment of neurological symptoms. When lamotrigine at a daily dose of 50 mg was co-administered to valproate and clozapine, the patient’s condition improved rapidly and remained stable over a follow-up period of 12 months. Concomitant administration of lamotrigine increased the serum levels of both valproate and clozapine. We conclude that

1. Normal lithium levels in co-medication with classical neuroleptics and concurrent medical illness are able to induce severe neurotoxicity.

2. Lithium re-administration after lithium-induced neurotoxicity should be strictly avoided.

3. Lamotrigine is safe when applied to patients with lithium-induced neurological sequelae.

4. Lamotrigine augmentation could enhance the efficacy of valproate and clozapine therapy to achieve antimanic action and mood stabilization in patients with refractory bipolar affective disorder.

5. Concomitant administration of lamotrigine interferes with the serum levels of both valproate and clozapine, thus implying continuous drug monitoring.

References

  • 1 Anderson G D, Yau M K, Gidal B E, Harris S J, Levy R H, Lai A A. et al . Bidirectional interaction of valproate and lamotrigine in healthy subjects.  Clin Pharmacol Ther. 1996;  60(2) 145-156
    CrossrefPubMedGoogle Scholar
  • 2 Bergmann L. Senior Medical Advisor, GlaxoSmithKline. 2001
    Google Scholar
  • 3 Berk M. Lamotrigine and the treatment of mania in bipolar disorder.  Eur Neuropsychopharmacol. 1999;  9 Suppl 4 S119-123
    CrossrefPubMedGoogle Scholar
  • 4 Bischof F, Melms A, Fetter M. Persistent cerebellar deterioration in a patient with lobar pneumonia under lithium, carbamazepine, and trifluperidol treatment.  Eur Psychiatry. 1999;  14(3) 175-176
    CrossrefPubMedGoogle Scholar
  • 5 Bowden C L, Lecrubier Y, Bauer M, Goodwin G, Greil W, Sachs G. et al . Maintenance therapies for classic and other forms of bipolar disorder.  J Affect Disord. 2000;  59 Suppl 1 S57-67
    CrossrefPubMedGoogle Scholar
  • 6 Brown E S, Thomas N R, Carmody T, Mahadi S, Nejtek V A. Atypical antipsychotics in bipolar and schizoaffective disorders.  Pharmacopsychiatry. 2001;  34(2) 80-81
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Calabrese J R, Bowden C L, McElroy S L, Cookson J, Andersen J, Keck PE J r. et al . Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder.  Am J Psychiatry. 1999;  156(7) 1019-1023
    PubMedGoogle Scholar
  • 8 Calabrese J R, Gajwani P. Lamotrigine and clozapine for bipolar disorder.  Am J Psychichatry. 2000;  157(9) 1523
    CrossrefPubMedGoogle Scholar
  • 9 Calabrese J R, Rapport D J, Shelton M D, Kujawa M, Kimmel S E. Clinical studies on the use of lamotrigine in bipolar disorder.  Neuropsychobiology. 1998;  38(3) 185-191
    PubMedGoogle Scholar
  • 10 Centorrino F, Baldessarini R J, Kando J, Frankenburg F R, Volpicelli S A, Puopolo P R. et al . Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.  Am J Psychiatry. 1994;  151(1) 123-125
    CrossrefPubMedGoogle Scholar
  • 11 Chong S A, Remington G. Clozapine augmentation: safety and efficacy.  Schizophr Bull. 2000;  26(2) 421-440
    PubMedGoogle Scholar
  • 12 Conca A, Beraus W, Konig P, Waschgler R. A case of pharmacokinetic interference in comedication of clozapine and valproic acid.  Pharmacopsychiatry. 2000;  33(6) 234-235
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Coryell W, Solomon D, Leon A C, Akiskal H S, Keller M B, Scheftner W A. et al . Lithium discontinuation and subsequent effectiveness.  Am J Psychiatry. 1998;  155(7) 895-898
    PubMedGoogle Scholar
  • 14 Dursun S M, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia.  Arch Gen Psychiatry. 1999;  56(10) 950
    PubMedGoogle Scholar
  • 15 Emilien G, Maloteaux J M. Lithium neurotoxicity at low therapeutic doses. Hypotheses for causes and mechanism of action following a retrospective analysis of published case reports.  Acta Neurol Belg. 1996;  96(4) 281-293
    PubMedGoogle Scholar
  • 16 Engle P M, Heck A M. Lamotrigine for the treatment of bipolar disorder.  Ann Pharmacother. 2000;  34(2) 258-262
    CrossrefPubMedGoogle Scholar
  • 17 Facciola G, Avenoso A, Scordo M G, Madia A G, Ventimiglia A, Perucca E. et al . Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders.  Ther Drug Monit. 1999;  21(3) 341-345
    CrossrefPubMedGoogle Scholar
  • 18 Freeman M P, Stoll A L. Mood stabilizer combinations: a review of safety and efficacy.  Am J Psychiatry. 1998;  155(1) 12-21
    PubMedGoogle Scholar
  • 19 Ghaemi S N. New treatments for bipolar disorder: the role of atypical neuroleptic agents.  J Clin Psychiatry. 2000;  61(Suppl 14) 33-42
    PubMedGoogle Scholar
  • 20 Grignon S, Bruguerolle B. Cerebellar lithium toxicity: a review of recent literature and tentative pathophysiology.  Therapie. 1996;  51(2) 101-106
    PubMedGoogle Scholar
  • 21 Kores B, Lader M H. Irreversible lithium neurotoxicity: an overview.  Clin Neuropharmacol. 1997;  20(4) 283-299
    PubMedGoogle Scholar
  • 22 Kossen M, Selten J P, Kahn R S. Elevated clozapine plasma level with lamotrigine.  Am J Psychiatry. 2001;  158(11) 1930
    CrossrefPubMedGoogle Scholar
  • 23 Maj M, Pirozzi R, Magliano L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors.  Am J Psychiatry. 1995;  152(12) 1810-1811
    PubMedGoogle Scholar
  • 24 Nemeroff C B. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder.  J Clin Psychiatry. 2000;  61(Suppl 13) 19-25
    PubMedGoogle Scholar
  • 25 Prior T I, Chue P S, Tibbo P, Baker G B. Drug metabolism and atypical antipsychotics.  Eur Neuropsychopharmacol. 1999;  9(4) 301-309
    PubMedGoogle Scholar
  • 26 Tondo L, Baldessarini R J, Floris G, Rudas N. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders.  Am J Psychiatry. 1997;  154(4) 548-550
    PubMedGoogle Scholar
  • 27 Walden J, Hesslinger B, van Calker D, Berger M. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder.  Pharmacopsychiatry. 1996;  29(5) 193-195
    PubMedGoogle Scholar
  • 28 Young A H, Macritchie K A, Calabrese J R. Treatment of bipolar affective disorder.  Bmj. 2000;  321(7272) 1302-1303
    CrossrefPubMedGoogle Scholar

Dr. med. Christoph Dembowski

Abteilung für Psychiatrie und Psychotherapie

Kreiskrankenhaus Rendsburg

Lilienstraße 20-28

24768 Rendsburg

Germany

Phone: ++49-4331 2008001

Fax: ++49-4331 2008010

      >